Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-02-04
DOI
10.1111/cas.14340
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KEYNOTE-025: Phase 1b Study of Pembrolizumab in Japanese Patients With Previously Treated PD-L1-Positive Advanced NSCLC
- (2019) Makoto Nishio et al. CANCER SCIENCE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO–JSOG joint study
- (2019) Hiroko Machida et al. GYNECOLOGIC ONCOLOGY
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.
- (2019) Scott S. Tykodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
- (2018) Karina Kulangara et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)
- (2018) Shinichi Komiyama et al. International Journal of Clinical Oncology
- Clear cell carcinomas of the ovary and kidney: clarity through genomics
- (2018) Jennifer X Ji et al. JOURNAL OF PATHOLOGY
- ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
- (2018) Jianfeng Shen et al. NATURE MEDICINE
- A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
- (2018) Deng Pan et al. SCIENCE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Identifying and managing the adverse effects of immune checkpoint blockade
- (2018) Arthur Winer et al. Journal of Thoracic Disease
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management
- (2018) Katsutoshi Oda et al. GYNECOLOGIC ONCOLOGY
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.
- (2018) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
- (2018) Andrea Varga et al. GYNECOLOGIC ONCOLOGY
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis
- (2017) Yoshiaki Maru et al. GYNECOLOGIC ONCOLOGY
- Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment Annual Report for 2009
- (2017) Toshiaki Saito et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
- (2017) Brooke E. Howitt et al. OncoImmunology
- The Dualistic Model of Ovarian Carcinogenesis
- (2016) Robert J. Kurman et al. AMERICAN JOURNAL OF PATHOLOGY
- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- Immune checkpoint inhibition in ovarian cancer
- (2016) Junzo Hamanishi et al. INTERNATIONAL IMMUNOLOGY
- Molecular Profiling of Clear Cell Ovarian Cancers
- (2016) Michael L. Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary
- (2014) Aikou Okamoto et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Clear cell carcinoma of the ovary: A review of the literature
- (2012) Marcela G. del Carmen et al. GYNECOLOGIC ONCOLOGY
- The association between endometriosis and ovarian cancer: A review of histological, genetic and molecular alterations
- (2011) Peter Svenssen Munksgaard et al. GYNECOLOGIC ONCOLOGY
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- (2011) Ignacio Varela et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now